11th International Conference on HIV Treatment and Prevention Adherence, Abstract No. 84



#### PrEP Prescribing and Adherence to Clinical Guidelines Among New York City Providers, 2015-2016

Paul M. Salcuni, MPH New York City Department of Health and Mental Hygiene Julie E. Myers, MD MPH Demetre C. Daskalakis, MD MPH Sarit A. Golub, PhD MPH Arjee J. Restar, MPH Zoe R. Edelstein, PhD MS



# Introduction

- Pre-exposure prophylaxis (PrEP) use is increasing in New York City (NYC), yet it is likely still under-prescribed
- NYC Health Dept. is committed to increasing access to PrEP through several programs, including outreach to providers
- Important to study provider practices, including adherence to clinical guidelines for PrEP follow-up care

K Scanlin, et al. CROI 2016. F Laufer et al. MMWR 2015. Z Edelstein, et al. IAPAC 2015, NHPC 2015.



#### Aims

- Among a sample of providers visited by a PrEP/PEP provider outreach campaign, we examined
  - Report of ever prescribing PrEP and its association with provider and practice characteristics
  - Among PrEP prescribers, adherence to CDC PrEP guidelines and its association with provider and practice characteristics

#### **CDC PrEP Guidelines Assessed**

At least **quarterly**: HIV testing, adherence counseling, risk reduction counseling, side effects assessment

At least **semi-annually**: STI screening, creatinine screening

# Methods

**Study population** Providers who received educational outreach visits from NYC DOHMH's PrEP/PEP Public Health Detailing Campaign (10/2014-4/2015)

- Visits: brief, "cold-call" presentations by DOHMH representatives using PrEP and PEP Action Kit
- Targeted practices with a recent history of diagnosing HIV
- Contacted primary care (PC) and infectious disease (ID) prescribing providers

**Survey design** One-time, self-administered Internet survey among sample of detailed providers (12/2015-1/2016)

**Sample recruitment** Sample of detailed providers were recruited via email with addresses obtained either:

- By representatives during the campaign or,
- Among a random sample, via Internet search or phone request

### **Data collection**

#### Outcomes

- Ever prescribing PrEP
- Adherence to CDC PrEP guidelines

#### Considering all your patients who are taking PrEP, how frequently do you do each of the following?

	Never	Only as needed	Every 3 mos.	Every 6 mos.	Every 12 mos.
Test for HIV	$\bigcirc$	$\bigcirc$	O	$\bigcirc$	$\bigcirc$
Test for STIs other than HIV	$\bigcirc$	$\bigcirc$	O	O	$\bigcirc$
Monitor creatinine clearance	$\bigcirc$	$\bigcirc$	O	0	$\bigcirc$
Ask about PrEP side effects	$\bigcirc$	$\bigcirc$	O	$\bigcirc$	$\bigcirc$
Provide PrEP adherence counseling	$\bigcirc$	$\bigcirc$	0	$\bigcirc$	$\bigcirc$
Provide risk reduction counseling	$\bigcirc$	$\bigcirc$	0	$\bigcirc$	$\bigcirc$

### Data analysis

- Associations with PrEP prescribing and adherence to CDC guidelines assessed using logistic regression, controlling for provider specialty and practice type
- Characteristics examined:

level

- Specialty (HIV medicine, ID, PC, other)
- Training (MD/DO, NP/PA)
- Graduation year (Before 1996, 1996 or later)
- Provider- Sexual identity (gay/lesbian/bisexual, straight)
  - PEP prescribing practices (ever prescribe, never)
    - Timing of initial PrEP prescription (before 2015, 2015 or later)
    - Number of PrEP patients (>5,  $\leq$ 5)
    - Knowledge/belief of PrEP efficacy (≥90% efficacious, <90%)
- Practice- **Practice type (hospital, community health center [CHC], independent)**
- level L Having a PrEP protocol (yes, no)

#### **Results – Provider sample**

Characteristic	n (%)	
Total	169 (100%)	
Provider specialty		
HIV	37 (22%)	
Infectious disease (ID)	15 (9%)	
Other	15 (9%)	
Primary care (PC)	102 (60%)	
Provider sexual identity		
Gay/lesbian/bisexual	16 (11%)	
Straight/heterosexual	131 (89%)	
Provider ever prescribed PEP		
Yes	90 (55%)	
No	74 (45%)	
Provider-reported belief of daily PrEP efficacy		
≥90%	89 (56%)	
0-89%	71 (44%)	
Practice type		
Hospital-affiliated	86 (57%)	
Community health center	41 (27%)	
Independent practice	23 (15%)	
Practice has PrEP protocol		
Yes	68 (44%)	
No	85 (56%)	

7

#### **Results – PrEP Prescribing**

Ever prescribed PrEP	Unadjusted OR	Adjusted* OR			
[n (%)]	(95% CI)	(95% CI)			
100/169 (59%)					
33 (89%)	8.3 (2.7 – 25.0)	9.8 (3.1 – 30.5)			
10 (67%)	2.0 (0.6 – 6.3)	2.6 (0.8 – 8.4)			
6 (40%)	0.7 (0.2 – 2.0)	0.5 (0.1 – 2.0)			
51 (50%)	Ref	Ref			
PEP					
76 (84%)	11.3 (5.3 – 23.9)	6.7 (2.9 – 15.5)			
24 (32%)	Ref	Ref			
52 (76%)	3.0 (1.5 – 6.1)	2.4 (1.1 – 5.3)			
44 (52%)	Ref	Ref			
Provider-reported belief of daily PrEP efficacy					
67 (75%)	<b>3.5 (1.8</b> – 6.9)	2.0 (1.0 – 4.3)			
33 (46%)	Ref	Ref			
15 (94%)	12.3 (1.6 – 95.7)	4.8 (0.6 – 41.9)			
72 (55%)	Ref	Ref			
	[n (%)] 100/169 (59%) 33 (89%) 10 (67%) 6 (40%) 51 (50%) PEP 76 (84%) 24 (32%) 52 (76%) 44 (52%) of daily PrEP efficacy 67 (75%) 33 (46%) 15 (94%)	[n (%)] (95% Cl) $100/169 (59%)$ $33 (89%) 8.3 (2.7 - 25.0)$ $10 (67%) 2.0 (0.6 - 6.3)$ $6 (40%) 0.7 (0.2 - 2.0)$ $51 (50%) Ref$ PEP $76 (84%) 11.3 (5.3 - 23.9)$ $24 (32%) Ref$ $52 (76%) 3.0 (1.5 - 6.1)$ $44 (52%) Ref$ $f daily PrEP efficacy$ $67 (75%) 3.5 (1.8 - 6.9)$ $33 (46%) Ref$ $12.3 (1.6 - 95.7)$			


#### p < 0.05


<sup>1</sup>Providers specializing in infectious diseases but not HIV medicine

<sup>2</sup>Other specialty includes all providers not identifying HIV medicine, ID, or primary care as a specialty (e.g., OB/GYN, pediatrics)

\*Adjusted for provider specialty and practice type (hospitals, CHCs, independent practices)

#### Proportion of PrEP prescribers reporting adherence to clinical guidelines





#### **Results – PrEP Guidelines**

	Follows PrEP guidelines	Unadjusted OR	Adjusted* OR		
Characteristic	[n (%)]	(95% CI)	(95% CI)		
Total	56/92 (61%)				
Timing of provider's f	irst PrEP prescription				
Before 2015	35 (76%)	3.9 (1.6 – 9.6)	4.3 (1.5 – 12.2)		
2015-2016	19 (45%)	Ref	Ref		
No. of provider's PrEP	P patients				
More than 5	39 (76%)	4.6 (1.9 – 11.3)	6.5 (2.2 – 19.3)		
≤5	17 (41%)	Ref	Ref		
Provider ever prescrik	ped PEP				
Yes	48 (68%)	3.4 (1.2 – 9.3)	3.7 (1.1 – 12.4)		
No	8 (38%)	Ref	Ref		
Provider reported belief of daily PrEP efficacy					
≥90%	46 (73%)	5.1 (2.0 – 13.2)	4.7 (1.6 – 13.6)		
0-89%	10 (34%)	Ref	Ref		
Practice has a PrEP pr	otocol				
Yes	35 (70%)	2.2 (0.9 – 5.3)	2.1 (0.8 – 5.5)		
No	21 (51%)	Ref	Ref		

#### p < 0.05

\*Adjusted for provider specialty and practice type (hospitals, CHCs, independent practices)

### Limitations

- Data based on self-report by providers
  - Subject to recall error and social desirability bias
- Convenience sample
  - Providers visited by Detailing Campaign were specifically targeted for greater impact
  - Providers who responded to Internet survey recruitment might have had greater interest in PrEP and PEP
- Data on patient-level characteristics not included
  - Providers may serve populations with different levels of PrEP eligibility



# Summary

- Though most NYC providers in this sample had prescribed PrEP (59%), less than two-thirds followed all CDC clinical guidelines examined
  - Nearly one quarter reported testing PrEP patients for HIV less frequently than every three months
- **PrEP prescribing** associated with:
  - Provider specializing in HIV medicine, ever prescribing PEP, and marginally, believing daily PrEP ≥90% efficacious
  - Practice having PrEP protocol
- Adherence to PrEP guidelines associated with:
  - Provider first prescribing PrEP before 2015, prescribing PrEP to >5 patients, ever prescribing PEP, believing daily PrEP ≥90% efficacious



### Discussion

- Findings concerning for suboptimal implementation of PrEP
  - Prescribing primarily by HIV specialists may limit access
  - Lack of adherence to guidelines may lead to development of drug resistance in those with breakthrough infection
- Findings motivate additional programs that support:
  - Further outreach to primary care providers
  - Continuing medical education among new and infrequent PrEP prescribers
  - Greater technical assistance on PrEP protocol development and implementation
  - Strategies for facilitating HIV testing outside of PrEP follow-up visits
  - Implementation of decision support tools in EMRs

# Acknowledgements

**Co-authors**: Julie Myers, Demetre Daskalakis, Sarit Golub, Arjee Restar, Zoe Edelstein

**DOHMH:** Mary Bassett, Jay Varma, Sue Blank, Adriana Andaluz, Michelle Dresser, Elizabeth Thomas, Mohini Persaud, Amanda Reid

**Detailers:** Maryellen Lively, Alex Cherisme, Gregory Gattereau, Jacqueline Kirkland, Stanford Smith, Jeffrey Watson

**Provider participants** 

Thank you!





#### **Conflict of Interest Disclosure**

Paul Salcuni has no real or apparent conflicts of interest to report.



Contact information Paul M. Salcuni psalcuni@health.nyc.gov

